January 20, 2023
Ono Pharmaceutical’s PD-1 antibody Opdivo (nivolumab) snatched the top position in the 2022 Japanese drug sales ranking with 152.3 billion yen (NHI price basis), outrunning MSD’s archrival Keytruda (pembrolizumab; 128.2 billion yen), the winner in 2021, according to Encise. Sales...read more